Flecainide in amyotrophic lateral sclerosis - a potential neuroprotective strategy.

Phase 2

Recruiting

• Conditions: Motor neuron disease; Amyotrophic lateral sclerosis; Neurological - Neurodegenerative diseases

• Registration Number: ACTRN12608000338369
• Lead Sponsor: South Eastern Sydney Illawarra Area Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-07-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Diagnosis of definite or probable amyotrophic lateral sclerosis according to the revised El Escorial criteria (as defined by the Committee on Neuromuscular
2. Diagnosis of possible amyotrophic lateral sclerosis according to the revised El Escorial criteria plus abnormally reduced short intracortical inhibition on transcranial magnetic stimulation.
3. Disease duration of less than five years.
4. Sniff nasal inspiratory pressure of greater than 50% predicted.
5. Normal cardiac rhythm (as determined by electrocardiograph) and left ventricular function (assessed by echocardiography).
6. Ability to provide consent.

Exclusion Criteria

1. History of dementia or major psychiatric disorder.
2. Involvement in other clinical trials
3. Pregnancy or lactation
4. History of cardiac disease.
5. Significant impairment of hepatic and/or renal function.
6. Any patient considered to be non compliant.

Study & Design

• Study Type: Interventional
• Study Design: Not specified